Treatment of Esthesioneuroblastoma and Nonsmall Cell Lung Cancer with Phenylbutyrate
Stanislaw R. Burzynski, Eva Nagy-Kubove
DOI: 10.4236/jct.2011.24071   PDF    HTML   XML   6,755 Downloads   12,656 Views   Citations


Esthesioneuroblastoma is a malignant tumor, arising in the upper nasal cavity, that could spread to the frontal lobe of the brain as well as metastasize to the lymph nodes. Due to the low incidence of this tumor, FDA-approved treatment modalities do not exist and clinical trials have not been performed. We present an interesting case of a 66-year-old female, diagnosed with Kadish stage B esthesioneuroblastoma and stage IIA nonsmall cell carcinoma of the lung, who benefited from our treatment. Both malignancies were diagnosed in 2002 at which time the patient consented to undergo left upper lobectomy for her lung cancer, but she refused the craniofacial resection and radiation therapy recommended for treatment of her esthesioneuroblastoma. From 2003 to 2004 she received treatment at the Burzynski Clinic with oral sodium phenylbutyrate (0.2 g/kg/day). She tolerated the treatment very well without significant adverse events. Gradual reduction in her tumor size was confirmed by repeat MRIs. From treatment start in March 2003 to December 2003 her tumor decreased by 40%. Subsequent MRI from March 2004 revealed increased tumor size, which, however, was still a 13% reduction from the baseline MRI. What is important to mention is that in addition to shrinkage of the esthesioneuroblastoma, the patient obtained the clinical benefit of 3.5-years longer survival than was predicted for her lung cancer—whereas the median survival for a patient with stage IIA adenocarcinoma of the left upper lobe of the lung is approximately two years, our patient survived more than five and a half years. The effect of phenylbutyrate (PB) and its metabolite phenylacetate on neuroblastoma and lung cancer is documented by numerous preclinical studies and is also evident in this case. It is proposed that the activity of these two compounds is mediated through increased expression of the p21 tumor suppressor gene. p21 is a strong inhibitor of cyclin-D and cyclin-dependent kinase 4, which contribute to undifferentiated phenotype in neuroblastoma and are instrumental in cell cycle progression from G1 to S phase. It is hoped that future research and combination of PB with other chemotherapeutic and targeted agents will provide better control of esthesioneuroblastoma and lung cancer.

Share and Cite:

S. Burzynski and E. Nagy-Kubove, "Treatment of Esthesioneuroblastoma and Nonsmall Cell Lung Cancer with Phenylbutyrate," Journal of Cancer Therapy, Vol. 2 No. 4, 2011, pp. 518-522. doi: 10.4236/jct.2011.24071.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] P. J. Bradley, N. S. Jones and I. Robertson, “Diagnosis and Management of Esthesioneuroblastoma,” Current Opinion in Otolaryngology & Head Neck Surgery, Vol. 11, No. 2, 2003, pp. 112-118. doi:10.1097/00020840-200304000-00009
[2] E. A. McElroy Jr., J. C. Buckner and J. E. Lewis, “Chemotherapy for Advanced Esthesioneuroblastoma: The Mayo Clinic Experience,” Neurosurgery, Vol. 42, No. 5, 1998, pp. 1023-1028. doi:10.1097/00006123-199805000-00040
[3] H. F. Biller, W. Lawson, V. P. Sachdev and P. Som, “Esthesioneuroblastoma: Surgical Treatment without Radiation,” Laryngoscope, Vol. 100, No. 11, 1990, pp. 1199-1201.
[4] D. Jethanamest, L. G. Morris, A. G. Sikora and D. I. Kutler, “Esthesioneuroblastoma: A Population-Based Analysis of Survival and Prognostic Factors,” Archives of Otolaryngology—Head & Neck Surgery, Vol. 133, No. 3, 2007, pp. 276-280. doi:10.1001/archotol.133.3.276
[5] MicroMedex Thomson Healthcare USP DI, “Cumulative List of Orphan Product Designations and Approvals: Phenylbutyrate and Phenylacetate,” Drug Information for the Healthcare Professional, Vol. 1, 2001, p. 3196.
[6] MicroMedex Thomson Healthcare USP DI, “Cumulative List of Orphan Product Designations and Approvals Phenylbutyrate and Phenylacetate,” Approved Drug Products and Legal Requirements, Vol. 3, 2001, pp. 1/5/39.
[7] S. C. Piscitelli, A. Thibault, W. D. Figg, A. Tompkins, D. Headlee, R. Lieberman, D. Samid and C. E. Myers, “Disposition of Phenylbutyrate and Its Metabolites, Phenyla-Cetate and Phenylacetylglutamine,” Journal of Clinical Pharmacology, Vol. 35, No. 4, 1995, pp. 368-373.
[8] M. A. Pelidis, M. A. Carducci and J. W. Simons, “Cytotoxic Effects of Sodium Phenylbutyrate on Human Neuroblastoma Cell Lines,” International Journal of Oncolology, Vol. 12, No. 4, 1998, pp. 889-893.
[9] M. A. Pelidis, M. A. Carducci and J. W. Simons, “Integration of Sodium Phenylbutyrate into Neuroblastoma Therapy,” 1996 ASCO Annual Meeting, Preclinical Experimental Therapeutics, Abstract 1596. &confID=29&abstractID=10357
[10] K. De Preter, S. De Brouwer, T. Van Maerken, F. Pattyn, A. Schramm, A. Eggert, J. Vandesompele and F. Speleman, “Meta-Mining of Neuroblastoma and Neuroblast Gene Expression Profiles Reveals Candidate Therapeutic Compounds,” Clinical Cancer Research, Vol. 15, No. 5, 2009, pp. 3690-3696. doi:10.1158/1078-0432.CCR-08-2699
[11] J. H. Schulte, S. Lim, A. Schramm, N. Friedrichs, J. Koster, R. Versteeg, I. Ora, K. Pajtler, L. Klein-Hitpass, S. Kuhfittig-Kulle, E. Metzger, R. Schüle, A. Eggert, R. Buettner and J. Kirfel, “Lysine-Specific Demethylase 1 Is Strongly Expressed in Poorly Differentiated Neuroblastoma: Implications for Therapy,” Cancer Research, Vol. 69, No. 5, 2009, pp. 2065-2071. doi:10.1158/0008-5472.CAN-08-1735
[12] A. J. Boivin, L. F. Momparler, A. Hurtubise and R. L. Momparler, “Antineoplastic Action of 5-Aza-2’-deoxy-cytidine and Phenylbutyrate on Human Lung Carcinoma Cells,” Anticancer Drugs, Vol. 13, No. 8, 2002, pp. 869-874. doi:10.1097/00001813-200209000-00013
[13] X. Zhang, L. Wei, Y. Yang and Q. Yu, “Sodium 4-Phenylbutyrate Induces Apoptosis of Human Lung Carcinoma Cells through Activating JNK Pathway,” Journal of Cell Biochemistry, Vol. 93, No. 4, 2004, pp. 819-829. doi:10.1002/jcb.20173
[14] T. H. Chang and E. Szabo, “Enhanced Growth Inhibition by Combination Differentiation Therapy with Ligands of Peroxisome Proliferator-Activated Receptor-Gamma and Inhibitors of Histone Deacetylase in Adenocarcinoma of the Lung,” Clinical Cancer Research, Vol. 8, No. 4, 2002, pp. 1206-1212.
[15] C. M. Lyon, D. K. Klinge, K. C. Liechty and S. A. Belinsky, “DNA Demethylating Agents and a PPAR-γ Agonist Cooperate to Induce Apoptosis in Lung Cancer Cell Lines, Cellular and Molecular Biology 2: DNA Methylation, Markers and Methylator Phenotype,” Proceedings of the American Association of Cancer Research, Vol. 47, 2006, Abstract 41.
[16] S. A. Belinsky, D. M. Klinge, C. A. Stidley, J. P. Issa, J. G. Herman, T. H. March and S. B. Baylin, “Inhibition of DNA Methylation and Histone Deacetylation Prevents Murine Lung Cancer,” Cancer Research, Vol. 63, No. 21, 2003, pp. 7089-7093.
[17] C. M. Lyon, D. M. Klinge, K. C Do, M. J. Grimes, C. L. Thomas, L. A. Damiani, T. H. March, C. A. Stidley and S. A. Belinsky, “Rosiglitazone Prevents the Progression of Preinvasive Lung Cancer in a Murine Model,” Carcinogenesis, Vol. 30, No. 12, 2009, pp. 2095-2099. doi:10.1093/carcin/bgp260
[18] N. Sidell, R. Wada, G. Han, B. Chang, S. Shack, T. Moore and D. Samid, “Phenylacetate Synergizes with Retinoic Acid in Inducing the Differentiation of Human Neuroblastoma Cells,” International Journal of Cancer, Vol. 60, No. 4, 1995, pp. 507-514. doi:10.1002/ijc.2910600414
[19] R. K. Wada, J. Huang, J. Yamashiro, L. Shimoda and N. Sidell, “Combination Therapy with Retinoic Acid and Phenylacetate Induces Differentation and Myc Down-Regulation in a Resistant Neuroblastoma Cell Line,” 88th Annual Meeting of the American Association for Cancer Research, San Diego, California, 1997, Abstract 581.
[20] N. Sidell, B. Chang, J. M. Yamashiro and R. K. Wada, “Transcriptional Upregulation of Retinoic Acid Receptor Beta (RAR Beta) Expression by Phenylacetate in Human Neuroblastoma Cells,” Experimental Cell Research, Vol. 239, No. 1, 1998, pp. 169-174. doi:10.1006/excr.1997.3889
[21] R. Wada, G. Han, T. Moore, D. Samid and N. Sidell, “Effects of Phenylacetate and Its Interaction with Retinoic Acid on Human Neuroblastoma Differentiation. Effects of Phenylacetate and Its Interaction with Retinoic Acid on Human Neuroblastoma Differentiation,” 85th Annual Meeting of the American Association for Cancer Research, San Francisco, California, April 1994, Abstract 2501.
[22] J. Cinatl, M. Mainke, A. Weissflog, H. Rabenau, B. Kornhuber and H. W. Doerr, “In Vitro Differentiation of Human Neuroblastoma Cells Induced by Sodium Phenylacetate,” Cancer Letter, Vol. 70, No. 1-2, 1993, pp. 15-24. doi:10.1016/0304-3835(93)90069-L
[23] J. J. Molenaar, M. E. Ebus, J. Koster, P. van Sluis, C. J. van Noesel, R. Versteeg and H. N. Caron,” Cyclin D1 and CDK4 Activity Contribute to the Undifferentiated Phenotype In Neuroblastoma,” Cancer Research, Vol. 58, No. 8, 2008, pp. 2599-2609. doi:10.1158/0008-5472.CAN-07-5032
[24] S. R. Burzynski, R. A. Weaver, T. Janicki., B. Szymkowski, G. Jurida, M. Khan and V. Dolgopolov, “Long-Term Survival of High-Risk Pediatric Patients with Primitive Neuroectodermal Tumors Treated with Antineoplastons A10 AS2-1,” Integrative Cancer Therapies, Vol. 4, No. 2, 2005, pp. 168-177. doi:10.1177/1534735405276835

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.